

## **Schedule D (I)** **(See rule 21(d) and rule 24(A)**

**Information and undertaking required to be submitted by the manufacturer or his authorized agent with the Application Form for a Registration Certificate. The format shall be properly filled in for each application in Form 40. The detailed information, secret in nature, may be furnished on a Computer Floppy.**

-----

### **1. Particulars of the manufacturer and manufacturing premises**

- 1.1 Name and address of the manufacturing premises(telephone no., Fax no., E-mail address) to be registered.
- 1.2 Name(s) and address(es) of the Proprietor/ Partners/ Directors.
- 1.3 Name and address of the authorised Agent in India, responsible for the business of the manufacturer.
- 1.4 A brief profile of the manufacturer's business activity, in domestic as well as global market.
- 1.5 A copy of Plant Master File (duly notarized)
- 1.6 A copy of Plant Registration/ approval Certificate issued by the Minister of Health/ National Regulatory Authority of the foreign country concerned (duly notarised)
- 1.7 A brief profile of the manufacturer's research activity.

### **2. Particulars of the manufactured drugs to be registered under Registration Certificate:-**

- 2.1 Names of drugs (Bulk/ Formulation/ Special product) to be registered meant for import into and use in India;
- 2.2 A copy of the approved list showing the bulk drugs/ formulations/ special products mentioned in 2.1 above are permitted for manufacturing/ marketing in the country of origin, (duly notarised);
- 2.3 A copy of Good Manufacturing Practice (GMP) certificate, as per WHO-GMP guidelines, or Certificate of Pharmaceutical Products (CPP), issued by the National Regulatory Authority of the foreign country concerned, in relation to the bulk drugs or formulations or special products, meant for import into India;
- 2.4 The domestic prices of the drugs to be registered in India, in the currency of the country of origin;
- 2.5 The name(s) of the drug(s) which are original research products of the manufacturer.

### **3. Undertaking to declare that:-**

- 3.1 We shall comply with all the conditions imposed on the Registration Certificate, read with rules 74 and 78 of the Drugs and Cosmetics rules, 1945.
- 3.2 We declare that we are carrying on the manufacture of the drugs mentioned in this Schedule, at the premises specified above, and we shall from time to

time report any change of premises on which manufacture will be carried on and in cases where manufacture is carried on in more than one factory any change in the distribution of functions between the factories;

3.3 We shall comply with the provisions of Part IX of the Drugs and Cosmetics Rules, 1945;

3.4 Every drug manufactured by us for import under the Registration Certificate into India shall be as regard strength, quality and purity conforms with the provisions of Chapter III of Drugs and Cosmetics Act, 1940 and Part IV of the Drugs and Cosmetics Rules, 1945, and their amendments from time to time;

3.5 We shall from time to time report for any change or manufacturing process, or in packaging, or in labeling, or in testing, or in documentation of any of the drugs, pertaining to the Registration Certificate, to be granted to us. Where any change in respect of any of the drugs under the Registration Certificate has taken place, in respect of any of the above matters, we shall inform the same to the licensing authority, in writing within 30 days from the date of such changes. In such cases, where there will be any major change/ modification in manufacturing or in processing or in testing, or in documentation, as the case may be, at the discretion of within 30 days by submitting a separate application, alongwith the registration fee as specified in clause (ii) of sub rule (3) of rule 24-A.

3.6 We shall from time to time report for any administrative action taken due to adverse reaction, viz. market withdrawal regulatory restriction, or cancellation of authorization and/ or “not of standard quality report” of any drug pertaining to the Registration Certificate declared by any Regulatory Authority of any country where the drug is marketed/ sold or distributed. The dispatch and marketing of the drug in such cases, shall be stopped immediately and the licensing authority shall be informed immediately. Further action in respect of stop marketing of drug shall be taken as per the directions of the licensing authority. In such cases, action equivalent to that taken with reference to the concerned drug(s) in the country of origin or in the country of marketing will be followed in India also, in consultation with the licensing authority. The licensing authority may direct any further modification to this course of action, including the withdrawal of the drugs from Indian market within 48 hours time period.

3.7 We shall comply with such further requirements, if any, as may be specified, by the Government of India, under the Act and the Rules, made thereunder.

3.8 We shall allow the licensing authority and/ or any person authorised by him in that behalf to enter and inspect the manufacturing premises and to examine the process/ procedure and documents in respect of any drug manufactured by us for which the application for Registration Certificate has been made;

3.9 We shall allow the licensing authority or any person authorised by him in that behalf to take samples of the drugs concerned for test, analysis or examination, if considered necessary by the licensing authority.

Place:.....

Date:.....

Signature of the manufacturer

Seal/Stamp